GLP-1受容体アゴニストを使用する成人のアデノマとセッシールソートポリップ検出率
Samita Garg1, Din Hoxha2, David Long1
1Department of Gastroenterology, Hepatology & Nutrition, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, OH.
Clinical and translational gastroenterology
|August 28, 2025
まとめ
グルカゴン型ペプチド-1受容体アゴニスト (GLP- 1RA) の使用は,特に糖尿病患者において,悪質な結腸鏡検査の準備と関連しています. これは,シシラ状のポリップの検出を減少させるかもしれないが,アデノマの検出は影響を受けない.
科学分野:
- 胃腸内科
- 内分泌学
- 薬理学について
背景:
- グルカゴン型ペプチド-1受容体アゴニスト (GLP- 1RA) は,糖尿病と肥満の管理に広く使用されています.
- GLP- 1RAは胃腸の運動を遅らせ,大腸内視鏡検査のための腸の準備の質を損なう可能性があります.
- 腸の準備が不十分である場合,大腸内視鏡検査で大腸内部の病変が欠けていくリスクが高くなります.
研究 の 目的:
- GLP-1RAの使用が腸の準備品質に与える影響を調査する.
- GLP-1RAがアデノマと状アデノマ (SSP) の検出率に及ぼす影響を評価する.
主な方法:
- コロノスコーピーを受けた49,987人の患者による遡及コホート研究.
- GLP-1RA使用者 (n=4,269) と使用しない者 (n=45,718) の比較
- 混同因子を制御するために,傾向スコアを重み付け,糖尿病状態によるサブグループ分析を行いました.
主要な成果:
- GLP- 1RAの使用は,不十分な排泄率の23%の増加と関連していました (OR1. 23).
- アデノマやSSPの検出率は,使用者と非使用者の間で有意な違いはありません.
- 糖尿病患者では,GLP- 1RAの使用により,不十分な準備率 (OR1. 88) とSSP検出率 (OR0. 71) が高かった.
結論:
- GLP- 1RAの使用は,特に糖尿病患者において,不十分な排泄率の増加と関連しています.
- 糖尿病のGLP- 1RA使用者において,SSPの検出率が低かった.
- 糖尿病のGLP- 1RA使用者のための調整された腸の準備プロトコルの将来的な評価は正当化されています.
関連する概念動画
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
255
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
255
Oral Hypoglycemic Agents: Glinides
256
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
256
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288


